Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

PurposeThe role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC) has not been clarified. A pooled analysis of prospective clinical trials was conducted to evaluate the efficacy and...

Full description

Bibliographic Details
Main Authors: Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant
non-small cell lung cancer
efficacy
safety
epidermal growth factor receptor-tyrosine kinase inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.586596/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.586596/full

Similar Items